文献速递消化系统肿瘤

胃癌KDM6A突变与表达和预后相关

[KDM6A mutation and expression in gastric cancer are associated with prognosis].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

研究通过二代测序分析57例胃癌组织,并结合公共数据库,探讨KDM6A突变或表达与临床病理特征及预后的关系。结果显示KDM6A突变或低表达患者生存时间更短,且与Borrmann分型、T分期、TNM分期和肿瘤直径相关,可能成为胃癌诊疗潜在靶点。

要点

  • KDM6A突变组中位生存53.5个月,短于未突变组72.0个月(P=0.007)。
  • KDM6A低表达患者中位生存短于高表达患者,多个数据库结果一致。
  • KDM6A突变与Borrmann分型、T分期、TNM分期和肿瘤直径显著相关。

核心结论

  • KDM6A突变或低表达的胃癌患者生存时间更短。
  • KDM6A突变和表达与胃癌临床病理因素相关,可能成为诊断及治疗的潜在靶点。

研究设计与样本

  • 对57例胃癌组织进行二代测序全外显子测序。
  • 结合Cbioportal、Kaplan Meier-Plotter和The Human Protein Atlas数据库进行生物信息学分析。

主要发现

  • 57例胃癌中KDM6A突变14例,突变率24.6%。
  • 突变组与未突变组在Borrmann分型、T分期、TNM分期和肿瘤直径差异有统计学意义(均P<0.05)。
  • 突变组中位生存时间53.5个月,短于未突变组72.0个月(P=0.007)。
  • Kaplan Meier-Plotter数据库875例中,低表达655例、高表达220例,低表达中位生存23.5个月短于高表达30.8个月(P=0.002)。

关键数值与推荐

  • Kaplan Meier-Plotter数据库:在男性、Ⅲ期、肠型、弥漫型、单纯手术治疗和含氟尿嘧啶方案化疗患者中,KDM6A表达与总生存时间有关(均P<0.05)。
  • The Human Protein Atlas数据库355例中,高表达97例、低表达258例,低表达中位生存13.7个月短于高表达19.8个月(P=0.022)。

临床怎么用

  • 对胃癌患者可考虑检测KDM6A突变和表达状态以辅助预后评估。
  • KDM6A可能作为胃癌诊断及治疗的潜在靶点,但需进一步验证。

局限性

  • 二代测序样本量仅57例,结论需更大样本验证。
  • 数据库分析为回顾性生物信息学分析,存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the relationship between KDM6A mutation or expression and clinicopathological characteristics of gastric cancer. Methods: Fifty-seven cases of gastric cancer tissues were analyzed by second-generation sequencing, and bioinformation database such as Cbioportal, Kaplan Meier-Plotter, and the Human Protein Atlas were used to analyze the relationship between KDM6A mutation and clinicopathological characteristics of gastric cancer. Results: Among 57 gastric cancer samples, 14 were KDM6A mutation, and the mutation proportion was 24.6%. Compared with the non-mutation group, the Borrmann classification, T stage, TNM stage and tumor diameter of KDM6A mutant group were significantly different (all P<0.05). The median survival time of the KDM6A mutant patients was 53.5 months, significantly shorter than 72.0 months of the KDM6A non-mutation patients (P=0.007). The analysis result of Kaplan Meier-Plotter database showed that, among all of the 875 patients, 655 patients had low KDM6A expression and 220 patients had high expression. The median survival time of patients with low expression was 23.5 months, significantly shorter than 30.8 months of patients with high expression (P=0.002). In male, gastric cancer patients with stage Ⅲ, intestinal type, diffuse type, simple surgical treatment and fluorouracil chemotherapy, the expression of KDM6A is related to the patient's overall survival time (all P<0.05). The analysis result of Cbioportal database showed that, among all of the 1 172 gastric cancer patients, 70 patients with KDM6A mutation, 1100 patients with non-mutation. The median overall survival time of mutant patients was 28.9 months, significantly shorter than 35.9 months of non-mutation patients (P<0.001). The analysis result of Human Protein Atlas database showed that, among all of the 355 gastric cancer patients, 97 patients had high KDM6A expression and 258 patients had low KDM6A expression. The median survival time of patients with low expression was 13.7 months, significantly shorter than 19.8 months of patients with high expression (P=0.022). Conclusions: The survival time of gastric cancer patients with KDM6A mutation or low expression is shorter. The mutation and expression of KDM6A are related to clinical pathological factors, which may become a potential target for the diagnosis and treatment of gastric cancer. 目的: 探讨KDM6A突变或表达与胃癌临床病理特征的关系及其对胃癌患者预后的影响。 方法: 通过二代测序对57例胃癌组织进行全外显子测序,以及Cbioportal、Kaplan Meier-Plotter和the Human Protein Atlas等生物信息数据库资料,分析KDM6A突变与胃癌临床病理特征和胃癌患者总生存时间的关系。 结果: 57例胃癌样本中,KDM6A突变14例,突变率为24.6%。突变组与未突变组比较,Borrmann分型、T分期、TNM分期和肿瘤直径差异有统计学意义(均P<0.05),突变组患者的中位生存时间(53.5个月)短于未突变组(72.0个月,P=0.007)。Kaplan Meier-Plotter数据库的875例胃癌患者中,KDM6A低表达者655例,高表达者220例,低表达患者的中位生存时间(23.5个月)短于高表达患者(30.8个月,P=0.002)。在男性、Ⅲ期、肠型、弥漫型、单纯手术治疗和含氟尿嘧啶方案化疗的患者中,KDM6A表达与患者的总生存时间有关(均P<0.05)。Cbioportal数据库的1 172例胃癌患者中,KDM6A突变者70例,未突变者1 100例,突变患者的总生存时间(28.9个月)短于未突变患者(35.9个月,P<0.001)。the Human Protein Atlas数据库的355例胃癌患者中,KDM6A高表达97例,KDM6A低表达258例,低表达患者的中位生存时间(13.7个月)短于高表达患者(19.8个月,P=0.022)。 结论: KDM6A突变、低表达胃癌患者的生存时间更短,且与临床病理因素相关,有可能成为胃癌诊断及治疗的潜在靶点。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li LL, Huang ZG, Wang YW, et al. [KDM6A mutation and expression in gastric cancer are associated with prognosis]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32867456. doi:10.3760/cma.j.cn112152-20190528-00334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。